問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

更新時間：2024-12-10

鄭偉宏醫師Cheng, Wei-Hong
  • Principal Investigator
  • Clinical Trial Experience (year)

  • 13520@s.tmu.edu.tw

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭偉宏醫師

List

4Cases

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    Capsules Intravenous Infusion Intravenous Infusion Capsules

Participate Sites
7Sites

Recruiting7Sites

2023-12-31 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-04-01 - 2022-06-30

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Terminated4Sites

2018-08-31 - 2026-05-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

  • Condition/Disease

    Triple-Negative Breast Cancer

  • Test Drug

    Atezolizumab (RO5541267)

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated9Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB